Reuters logo
BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone
September 7, 2017 / 12:00 PM / 14 days ago

BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone

Sept 7 (Reuters) - Intra-cellular Therapies Inc

* Announces positive topline data from 6-week open-label safety switching study with Lumateperone in patients with schizophrenia​

* statistically significant improvements observed in patients with stable schizophrenia symptoms when switched to Lumateperone​

* Lumateperone was generally well tolerated with a favorable safety profile​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below